Conference Coverage
Conference Coverage
Particulate pollution increases the risk for breast cancer
“There is now strong epidemiological and biological evidence for the link between PM2.5 particulate exposure and cancer ...”
Conference Coverage
T-DXd benefits persist for HER2-low breast cancer
Extended follow-up of DESTINY-Breast04 confirms survival benefit of T-DXd for HER2-low advanced breast cancer.
Conference Coverage
Omitting surgery may be safe in early BC after neoadjuvant pCR
A small trial in early breast cancer has reported 100% disease-free survival at 3 years in women who skipped surgery following pathologic complete...
Conference Coverage
Dato-DXd trumps chemo in advanced HR+/HER2– breast cancer
The antibody-drug conjugate datopotamab deruxtecan had better efficacy and safety than chemotherapy for patients with endocrine-resistant...
Conference Coverage
The sobering facts about alcohol and cancer
An ESMO session highlights the well-known links between alcohol consumption and cancer and calls on healthcare professionals to do more to raise...
Conference Coverage
ICIs improve pCR rates in early ER+/HER2– breast cancer
Nivolumab and pembrolizumab boosted pathologic complete response rates when added to neoadjuvant and adjuvant therapy in patients with high-risk...
Conference Coverage
No benefit to adding ICI to chemo in triple-negative breast cancer: study
There were no differences in 5-year event-free survival among patients with TNBC who received neoadjuvant chemotherapy with or without...
Conference Coverage
Remote symptom monitoring in advanced cancer improves quality of life
Building on prior studies, a new trial shows that digital symptom monitoring during cancer treatment detects symptoms early, improves quality of...
Conference Coverage
Fasting during breast cancer chemo improves quality of life
Short-term fasting around the time of chemotherapy is a promising supportive therapy during breast cancer chemotherapy that may enhance quality of...
Conference Coverage
Adjuvant abemaciclib-ET combo shows long-term benefit in high-risk early breast cancer
Invasive disease–free and distant recurrence–free survival were better with the CDK4/6 inhibitor plus endocrine therapy than endocrine therapy...